醫渡科技(02158.HK)中標華潤生物醫藥I期臨牀試驗項目
格隆匯10月26日丨醫渡科技(02158.HK)公吿,近期,醫渡科技聯屬公司天津開心生活科技有限公司中標華潤生物醫藥有限公司的評估CRB4101片在健康成人受試者中單次給藥的安全性、耐用性、藥代動力學和藥效動力學特徵的I期臨牀試驗項目,並已簽訂合同。合同金額為人民幣1367.5萬元。
中國醫療產業正在經歷從醫療信息化到醫療智能化的發展轉型過程中。醫渡科技是中國醫療智能行業領導者,秉持"使價值導向的精準醫療惠及每一個人"的使命,自成立初即專注於醫療智能開發與應用,致力於促進構建安全、普惠、價值導向的智能醫療體系。醫渡科技通過自主研發的"醫療智能大腦"YiduCore,賦能研究、診療、公共衞生三大醫療場景,為醫療行業提供智能分析驅動的創新解決方案,助力加速醫療服務降低成本,提升醫療行業供給端的效率。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.